Epsilogen Ltd was pleased to host representatives from the US Advanced Research Projects Agency for Health (ARPA-H) at its facilities. The team welcomed Amy Lin, Director of the Division of International Affairs at ARPA-H, and Taeko Noah, PhD, Technical SETA, for a visit that included discussions on ongoing collaboration and a tour of the company’s operations.
Since 2024, ARPA-H has been working with TigaTx, Inc., a wholly owned subsidiary of Epsilogen, to advance the development of TigaTx’s engineered monomeric IgA neutrophil engagers for cancer, alongside engineered dimeric IgA therapeutics targeting infectious diseases.